Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer David Hyman Acquires 20,000 Shares

Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report) Senior Officer David Hyman purchased 20,000 shares of the company's stock in a transaction on Thursday, January 9th. The shares were purchased at an average price of C$1.45 per share, for a total transaction of C$29,000.00.

Medicenna Therapeutics Stock Performance

Shares of TSE:MDNA traded down C$0.08 during midday trading on Friday, reaching C$1.37. The company's stock had a trading volume of 174,066 shares, compared to its average volume of 82,477. The company has a quick ratio of 4.65, a current ratio of 2.51 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average of C$1.80 and a 200 day moving average of C$2.01. Medicenna Therapeutics Corp. has a twelve month low of C$0.40 and a twelve month high of C$2.98. The firm has a market capitalization of C$104.71 million, a PE ratio of -3.61 and a beta of 1.21.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.